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ABSTRACT
Objective: A pilot open label, single dose trial of
fenobam, an mGluR5 antagonist, was conducted to
provide an initial evaluation of safety and pharmacoki-
netics in adult males and females with fragile X syndrome
(FXS).
Methods: Twelve subjects, recruited from two fragile X
clinics, received a single oral dose of 50–150 mg of
fenobam. Blood for pharmacokinetic testing, vital signs
and side effect screening was obtained at baseline and
numerous time points for 6 h after dosing. Outcome
measures included prepulse inhibition (PPI) and a
continuous performance test (CPT) obtained before and
after dosing to explore the effects of fenobam on core
phenotypic measures of sensory gating, attention and
inhibition.
Results: There were no significant adverse reactions to
fenobam administration. Pharmacokinetic analysis
showed that fenobam concentrations were dose depen-
dent but variable, with mean (SEM) peak values of 39.7
(18.4) ng/ml at 180 min after the 150 mg dose. PPI met
a response criterion of an improvement of at least 20%
over baseline in 6 of 12 individuals (4/6 males and 2/6
females). The CPT did not display improvement with
treatment due to ceiling effects.
Conclusions: Clinically significant adverse effects were
not identified in this study of single dose fenobam across
the range of dosages utilised. The positive effects seen in
animal models of FXS treated with fenobam or other
mGluR5 antagonists, the apparent lack of clinically
significant adverse effects, and the potential beneficial
clinical effects seen in this pilot trial support further study
of the compound in adults with FXS.
Fragile X syndrome (FXS) is the most common
inherited form of intellectual disability, autism,
and learning disability, with a broad range of
severity and full mutation gene frequency of
1/2500.
1 FXS results from an unstable trinucleotide
repeat expansion of .200 CGG repeats (full
mutation) in the promoter of the FMR1 (fragile X
mental retardation–1) gene
2 which leads to tran-
scriptional silencing of FMR1 and thus, absence or
significant reduction of the FMR1 protein (FMRP).
3
Because FMR1 is located on the X chromosome,
females with a full mutation are more mildly
affected than males, due to production of FMRP
from the normal FMR1 allele on the non-mutated
X chromosome. FMRP is an RNA binding protein
which modulates dendritic maturation and
synaptic plasticity through mechanisms including
inhibition of group 1 metabotropic glutamate
receptor (mGluR1 and mGluR5) mediated mRNA
translation in dendrites.
4–7 Numerous expected
consequences of excessive activation of mGluR
mediated dendritic protein synthesis due to loss of
inhibitory control by FMRP are found in the fmr1
knockout mouse, including enhanced mGluR
activated hippocampal
8 and cerebellar
9 long term
depression (LTD), reduction of synaptic AMPA
receptors,
10 immature appearing elongated dendri-
tic processes,
11 12 and abnormal epileptiform dis-
charges.
13 Further, many phenotypic features of
FXS are predicted effects that would occur in a
setting of enhancement of mGluR mediated pro-
cesses, including seizures, epileptic abnormalities
on electroencephalograms (EEGs), cognitive pro-
blems, strabismus, enhanced anxiety, perseverative
behaviours, coordination problems, hypersensitiv-
ity to tactile stimuli, and even loose stools.
10
Consistent with this underlying mechanism of
mGluR overactivity in FXS, MPEP (2-methyl-6-
(phenylethynyl)-pyridine) and other mGluR nega-
tive modulators have been shown to reverse
multiple phenotypes in the fmr1 knockout mouse,
including audiogenic seizures, epileptiform dis-
charges and open field hyperactivity,
13 14 as well
as impairments in courtship memory in dfxr
mutant Drosophila
15 models. Genetic down regula-
tion of mGluR5 expression by crossing the fmr1 KO
mouse with mGluR5 heterozygous knockouts
16
also reverses these and other phenotypes including
dendritic spine changes, ocular dominance plasti-
city, and excessive protein synthesis.
Although mGluR5 negative modulators are not
currently available for treatment of humans with
FXS, during recent high throughput lead-finding
screens, Porter et al
17 discovered that fenobam is a
high potency and highly selective mGluR5 antago-
nist, comparable to MPEP, with no relevant effects
on a panel of 86 central nervous system (CNS)
receptors assayed in a commercial receptor binding
screen, including other mGluRs. Fenobam was
previously investigated as an anxiolytic in a
number of phase II studies in the early 1980s.
18–20
These studies revealed a mixed picture of anxio-
lytic efficacy, with double blind, placebo controlled
trials variously reporting the compound as active
or inactive. This discrepancy was not easily
reconciled based on patient numbers, dose level,
duration of treatment, or outcome measures.
There were no major safety concerns although a
number of subjects taking doses of 150 mg four
times daily of fenobam for up to 4 weeks did
describe odd CNS related perceptual phenomena,
such as hallucinations, vertigo, paraethesias, and
insomnia.
Given the likelihood that fenobam would
target a specific underlying mechanism of neural
Original article
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to provide an initial evaluation of the safety and pharmacoki-
netics of fenobam in adult males and females with FXS, and to
explore effects of fenobam on core phenotypic measures of
sensory gating, attention and inhibition in FXS. The CNS side
effects previously reported in clinical studies with fenobam have
the potential to be subjectively distressing. FXS represents a
vulnerable patient population with impaired understanding and
communication skills. Negative modulators of the mGluR5
receptor are capable of producing morphological and beha-
vioural changes after a single dose.
21 22 Accordingly we felt it
most appropriate to examine the effects of fenobam in patients
with FXS with a single dose in this first clinical trial of an
mGluR5 antagonist.
METHODS
Subjects were recruited from fragile X clinics at Rush University
Medical Center (RUMC) and the MIND Institute at University
of California at Davis Medical Center (UCDMC). Inclusion
criteria required a DNA based diagnosis of FXS, stable
medication doses for at least 6 weeks before study, and ability
to tolerate an intravenous catheter (IV) for 6 h for pharmaco-
kinetic studies. Exclusion criteria included concurrent treatment
with lithium, typical antipsychotics, tricyclic antidepressants,
NMDA antagonists or enzyme inducing anticonvulsants,
concurrent or recent initiation of cognitive behavioural therapy,
significant disease in another organ system, hearing or vision
impairments, psychosis, major depressive symptoms, preg-
nancy, drug abuse disorder, Tourette syndrome, and significant
abnormalities in baseline laboratory tests. Subjects with well
controlled seizures were not excluded although none of the
subjects enrolled had a seizure history. Informed written
consent was obtained from either the subject or the parent
before participation. Assent from the subject was obtained
when the subject was not his/her own legal guardian. The study
was approved by the institutional review boards at RUMC and
UCDMC. The sequence of subject enrolment and treatment
was random, depending only on when subjects contacted the
study centre and when they could be scheduled.
At the screening visit medical history, exam, vital signs,
laboratory testing including routine chemistries, blood counts,
thyroid functions, electrocardiogram (ECG), and a pregnancy
test (females) were evaluated, and baseline CPT (Carolina
Project Fragile X continuous performance test) and prepulse
inhibition (PPI) outcome measures were obtained. At the
treatment visit, 14–28 days after screening, an IV was inserted
for blood drawing and the subject received the study medication
orally. Blood for pharmacokinetic testing, blood pressure, heart
rate and side effect screening was obtained at 0, 15, 30, 45, 60,
120, 180, 240, 300, and 360 min after dosing. Our side effects
screening protocol involved asking both the subject and family
members if the subject was having any of a structured list of
symptoms relevant to potential effects of fenobam (aggression,
fatigue, hyperactivity, anxiety and fidgetiness, increase in self
stimulation, odd behaviour, inappropriate laughter, dizziness,
vertigo, nausea, paraesthesia, and headache), and direct obser-
vation by the physician and family for the above symptoms and
other behavioural changes. Subjects were all verbal and
sufficiently high functioning to report side effects in response
to simple questions. Post-treatment PPI was performed after the
60 min blood sampling, followed by CPT. The first subject for
each gender was dosed with 50 mg fenobam, the second with
100 mg, and all subsequent subjects with 150 mg. The final
dosage of 150 mg fenobam was at the middle range of individual
doses in previous studies where CNS side effects were observed.
Conference calls were held after each subject was dosed, to
confirm absence of adverse events and justify dose escalation or
maintenance for the subsequent subject of that gender.
PPI was chosen as an outcome measure to assess sensorimotor
gating and inhibitory control because: (1) there is significant
deficit of PPI in males and females with FXS
23 24; (2) PPI at
120 ms has excellent test-retest reliability with intraclass
correlations of 0.85 for FXS and 0.88 for controls
24; (3) PPI is
responsive to medication effects
25 26; (4) PPI in the mouse model
of FXS can be corrected with MPEP
21; and (5) PPI represents an
electrophysiological measure that is expected to be less
amenable to placebo effects than other measures. The PPI
protocol used for this study was a slightly modified version of
the procedure previously described.
24 Startle stimuli (SS) were
50 ms 105 db SPL white noise pulses and acoustic prepulses (PP)
are 25 ms 75 db SPL 1 kHz tones. These trials are delivered
while participants watch a silent movie to maintain compliance
and interest in the procedure. Test-retest studies have demon-
strated good to excellent reliability for PPI at 120 ms and
240 ms, but inadequate reliability for PPI at 60 ms. Therefore,
for the current study, we eliminated the 60 ms trial type and
added two trials per type, resulting in a protocol with 30 total
trials (10 with SS alone, 10 with 120 ms prepulse and 10 with
240 ms prepulse). Digitised obicularis oculi electromyographic
peak magnitudes recorded between 20 ms and 200 ms post
startle probe onset were averaged across trials within each type.
PPI was calculated as: 100 6[(mean response magnitude in the
startle stimulus alone trials – mean response magnitude in the
prepulse trials)/mean response magnitude in the startle stimu-
lus alone trials]. Based on group differences obtained in our prior
study and review of the literature on PPI reliability and its
response to psychopharmacological intervention, we deter-
mined a priori that subjects with PPI improvement of 20% on
the 120 ms trials (the most reliable trial latency) or more would
be considered responders.
The Carolina Fragile X Project Continuous Performance Test
(FXCPT), developed for individuals with cognitive impairment,
was chosen to assess attention, impulsivity, and inhibition, as
other more standard CPT measures are too difficult for
individuals with FXS.
27 The FXCPT showed a significant deficit
in response inhibition in males with FXS, compared to mental
age matched controls,
28 and in a test-retest reliability study had
a weighted kappa of 0.7, suggesting a good reproducibility.
29 The
FXCPT was administered as previously described
28 29 and the
number of correct hits on a target stimuli, omissions involving
lack of reaction to a target (attention deficit), and commissions
involving reacting to a non-target (impulsivity, poor inhibitory
control) were tabulated. Individuals with FXS often hit the
mouse button repeatedly and impulsively, thus achieving a
perfect number of hits with low omission scores, but a poor
overall performance due to a high number of commission
errors.
29 Thus, the commission score was the main focus of the
analysis, as the more reliable marker for abnormal performance
on the FXCPT.
Fenobam concentrations from plasma samples were measured
with MS-MS based assays validated for human application,
using positive ion liquid chromatography/mass spectrometry/
mass spectrometry (LC/MS/MS). For comparison, plasma
samples over 24 h were obtained from three healthy adult male
volunteers.
For statistical analysis of PPI data, a positive response was
defined as a 20% or greater improvement over baseline. One
sample exact binomial 95% confidence interval was computed
Original article
J Med Genet 2009;46:266–271. doi:10.1136/jmg.2008.063701 267for the proportion of positive response. A one sample two sided
exact hypothesis test was used to compare the proportion of
positive response to the null proportion of 2/13 (15.4%),
obtained from our prior PPI study with untreated individuals
with FXS.
24
RESULTS
Six males and six females with FXS (three males and three
females at each site; mean (SD) age 23.9 (5.4) years, range 18.7–
30.7 years) were screened and enrolled. There was wide
variability in cognitive ability, with IQs ranging from 36–85,
as would be expected in a study enrolling both males and
females with FXS. No subjects dropped out or failed to meet
entry criteria. There were no clinically significant abnormalities
of the examination, vital signs, or laboratory or ECG parameters
at baseline. Demographic data are given in table 1.
There were no significant adverse reactions to fenobam.
Particularly, adverse events (listed in Methods) in relation to
altered CNS function were not seen. Three subjects experienced
mild sedation (table 1). In nine of the 12 cases calmed behaviour
was observed with improvement in eye contact, ability to
interact, anxiety and/or motor overactivity (table 1).
PPI for the 120 ms trials met response criterion of at least 20%
improvement over baseline in six of 12 individuals (four of six
males and two of six females, table 1) with 95% confidence
interval of 21.1% to 78.9%. Improvements ranged from 23.7% to
44.2% (fig 1). The proportion of positive response (at least 20%
improvement after fenobam) was significantly greater than that
expected in untreated individuals (p=0.01), which was found
to be 15.4% (2/13) based on a prior study
24 consisting of a
similar cohort of individuals with FXS who underwent test-
retest on the PPI utilising the same methodology in the absence
of intervention (fig 1).
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Figure 1 Change in prepulse inhibition (PPI) in adults with fragile X
syndrome (FXS) after single dose fenobam compared to variation in a
prior control group with FXS (18.70 (9.56) years) that underwent test-
retest with a similar PPI protocol performed at the same study sites over
the same time frame.
24 Four of six males (67%) and two of six females
(33%) had PPI increases of 20% or more (improvement criterion) after
fenobam compared to two of 13 with FXS (15%) in the test-retest control
group.
Original article
268 J Med Genet 2009;46:266–271. doi:10.1136/jmg.2008.063701As expected, most subjects (10 on auditory FXCPT, nine on
visual FXCPT) had a 100% rate of hits at baseline. The rate of
commissions was also low, with only one subject on auditory
FXCPT and one on the auditory and visual FXCPT showing
more than two commission errors at baseline. Thus, there were
no significant changes between baseline and treatment in
FXCPT performance due to ceiling effects. However, the most
impaired subject on this task did show a decrease in commis-
sions (from 18 to 12 on visual FXCPT and 26 to six on auditory
FXCPT).
Pharmacokinetic analysis in subjects with FXS showed that
fenobam values were dose dependent but variable, with mean
(SEM) peak concentrations following administration of 150 mg
of fenobam being 39.7 (18.4) ng/ml at 180 min post dose. The
mean peak plasma concentration of fenobam did not differ from
that seen in normal volunteers (n=3). Upon visual inspection
the timing to mean peak concentrations was similar in FXS
patients and in normal controls (fig 2). Neither fenobam dose
nor concentrations after 60 or 120 min correlated with
improvement in PPI.
DISCUSSION
To our knowledge this is the first study assessing safety and
pharmacokinetic metabolism of an mGluR5 antagonist in
humans with FXS. Administration of a single dose to this cohort
of 12 adults did not result in significant adverse events. Although
the doses of 100 mg to 150 mg are within the range (100–
600 mg) of single fenobam doses previously investigated in
patients with anxiety disorders, and despite extensive question-
ing of subjects and parents, side effects described in previous
studies were not observed. The pharmacokinetics of fenobam
showed wide intersubject variability, as previously noted in
normal volunteers and patients with anxiety disorders. Peak
plasma concentrations in this study ranged from 3.28–113 ng/ml
(5.3–220 ng/ml in prior studies
20) which overlays the concentra-
tion range at which fenobam interacts with the mGluR5
receptor.
17 Peak plasma times occurring around 2–3 h were
slightly longer than reported previously (0.33–2 h).
20
In a subset of subjects, calmed behaviour was observed within
an hour after fenobam dosing, before the mean peak plasma
concentration of fenobam. The observation of rapid reduction
in hyperactivity and anxiety after fenobam dosing in the most
affected subjects with FXS was particularly surprising.
Similarly, it was remarkable that 50% of our cohort demon-
strated at least a 20% improvement in PPI whereas only 15.4%
(two of 13) of untreated individuals with FXS and 0% of normal
controls (0 of 16) had 20% or more increase in PPI in test-retest
studies. PPI improved in subjects treated with 50, 100, or
150 mg of fenobam (table 1), consistent with variable
pharmacokinetics of the drug and suggesting that, as with
many psychoactive drugs, effective dosing may be highly
variable in different individuals. Similarly, clinical responsive-
ness was variable and not specific to the dosage used in this
study. Five of the six individuals with improved PPI also showed
a subjective clinical improvement and one did not, and four
individuals showed clinical improvement but not an improved
PPI, so there was not complete concordance between PPI and
clinical improvement. However, PPI was only done at 1 h post
dosing, when fenobam values had not yet peaked, and clinical
assessment was continuous for 6 h after the dosing; therefore,
clinical observations were likely more sensitive, given the
pharmacokinetic variability of fenobam, but the PPI data are
less subject to placebo effect and thus provide a useful
additional indicator of response.
The rapid improvement in PPI is consistent with prior studies
suggesting that PPI can respond acutely to drug treatments;
children with ADHD showed improvement in PPI after a single
dose of methylphenidate,
25 and mGluR agonists produce rapid
(within 30 min of treatment) normalisation of PPI in the
knockout mouse model of FXS.
21 Thus, although more
Figure 2 Plasma concentrations of fenobam following oral
administration. Panel A shows plasma values in n=3 male healthy adult
volunteers administered a single dose of 150 mg fenobam monohydrate.
The mean (SEM) plasma concentration achieved was 67.1 (37.8) ng/ml
at 120 min post dose. Healthy volunteers were tested through a different
phase I pharmacokinetic study of the formulation of fenobam to be used
in the fragile X syndrome (FXS) study. These individuals were tested at
Qualia Clinical Services, Inc, Nebraska, USA, during 2007 after they
signed informed consent. The protocol for pharmacokinetic testing in the
volunteers was approved by the Qualia Clinical Services Inc independent
institutional review board (IRB) and submitted to the US Food and Drug
Administration. Time points for collection of the pharmacokinetic data
were slightly different from those used in the subjects with FXS. Panel B
shows plasma values of fenobam following administration of 50 mg
(n=2), 100 mg (n=2) and 150 mg (n=8) to male and female adults
with FXS. Samples were obtained from patients during the duration of a
single outpatient visit. Following administration of 150 mg fenobam to
patients the mean (SEM) plasma concentration achieved was 39.7
(18.4) ng/ml at 180 min post dose. The difference between mean peak
values after administration of 150 mg fenobam was not significant when
normal healthy adults males were compared to subjects with FXS
(t=0.47, df=2, p=0.67). The mean peak plasma values obtained after
administration of 150 mg fenobam to males and females with FXS were
also not significant (t=0.28, df=6, p=0.79). Panel C shows mean
(SEM) plasma values achieved following administration of 50 mg
(n=2), 100 mg (n=2) and 150 mg (n=8) fenobam monohydrate in
male and female adult patients with FXS. The mean peak plasma value
achieved was related to dose.
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improvement would be expected to take much longer, PPI may
be at least partially dependent on rapid changes in neurotrans-
mitter and neuroreceptor expression modulating short term
synaptic plasticity.
Fenobam peak concentrations occurred later than expected
based on prior pharmacokinetic results and thus the PPI was
done when values were still increasing on the pharmacokinetic
curve. Therefore, the PPI results presented may represent an
underestimate of the effect of fenobam on PPI that would have
been measured if PPI was done at 2–3 h post-dose. Further,
correlations between PPI and fenobam values may have been
masked due to variable rates of increase in different subjects. In
future study design for fenobam trials, PPI should be adminis-
tered 2–3 h post-dose to optimise drug impact. The PPI results
shown here are consistent with a recent study using eyeblink
startle PPI methodology, similar to methods used in human
studies, which demonstrated a significant PPI deficit in the fmr1
knockout mouse that was rescued to wild-type levels by MPEP,
an mGluR5 antagonist.
21
The poor correlation of PPI improvement with fenobam
values, and the observation of behavioural and PPI responses
well before the peak level of fenobam was reached, could be due
to rapid generation of an active metabolite with a variable rate
of conversion or because the observed change was unrelated to
fenobam. As expected, PPI results for females are more variable
than males, likely due to neuronal and brain circuit mosaicism
for FMRP production. Thus, depending on brain patterns of
FMRP mosaicism, PPI deficits (and rescue) would not necessa-
rily be correlated with cognition in females with FXS.
Although the FXCPT did not show significant changes from
baseline to treatment conditions in the averaged group results,
some individual improvements in commission errors were
observed. This CPT is not sufficiently sensitive to be used as
an outcome measure in relatively high functioning cohorts of
subjects with FXS due to ceiling effects. Additional work is
needed to identify a CPT that functions as a measure of
attention and inhibition across the entire spectrum of involve-
ment in FXS as well as other outcome measures, such as a
validated FXS specific scale directed at measuring change in
behavioural phenotypes prominent in FXS.
Limitations of this study include the lack of placebo control,
the small sample size, and the biasing of the subject sample to
include only those who were higher functioning behaviourally
and less anxious so that they would be able to tolerate the study
procedures, including the intravenous catheter. More anxious
individuals with FXS might be expected to show a more obvious
response to the drug, but would not have tolerated this
protocol. Also, there may have been limitations in the ability
of subjects to describe side effects despite the extensive
measures taken to elicit these, and the study does not rule out
side effects that might emerge with chronic dosing, as in cohorts
treated with fenobam in the 1980s. Nonetheless, the lack of
safety problems seen in this study should encourage further
studies of fenobam, starting at low doses and with careful
titration based on efficacy and tolerability, in patients with
FXS—given the remarkable benefits of mGluR5 negative
modulators with respect to behaviour, cognition and even
dendritic structure in animal models of FXS. It is hoped that
long term use of fenobam will similarly rescue synaptic
plasticity deficits in humans with FXS, and that PPI improve-
ment observed here signals enhanced frontal gating, which with
long term treatment could lead to improved information
processing and cognition. To effect long term improvements
in cognition, pharmacological treatment will likely require
concomitant learning programmes to provide the substrate for
the stimulus dependent synaptic remodelling presumably
facilitated by the mGluR5 blocker. This will necessitate re-
initiation of learning programmes for adults and emphasises the
need to work toward trials of fenobam in children, who are still
in school, and are earlier in the course of the effects of FXS on
synaptic plasticity.
In summary, this trial did not find major safety concerns to a
single administration of fenobam in FXS, and suggested that
clinical improvements in behaviour and PPI may be seen even
after a single dose. This would indicate that placebo controlled
trials of fenobam and other mGluR5 antagonists involving
longer term treatment of individuals with FXS should be
considered to investigate whether rescue of the FXS phenotype
observed in animal models can be extended to humans.
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